尿细胞学在血尿检查中还有作用吗?
尿细胞学诊断膀胱癌和上尿路尿路上皮癌的敏感性43.5%、特异性95.7%、PPV 47.6%、NPV 94.9%,漏诊21例膀胱癌和5例UTUC。结论提示尿细胞学不应作为血尿检查的常规项目。
要点
- 尿细胞学诊断膀胱癌和UTUC敏感性仅43.5%,漏诊率高。
- 尿细胞学联合CTU敏感性90.2%,优于联合RBUS的66.7%。
- 假阳性导致54.5%患者接受进一步有创检查,未见癌症。
核心结论
- 尿细胞学会漏诊相当数量的肌层浸润性膀胱癌和高危病变,不建议作为血尿检查的常规项目。
- 在特定病例中考虑尿细胞学时,需权衡假阳性结果导致进一步有创检查的影响。
研究设计与样本
- DETECT I研究(NCT02676180)为多中心前瞻性观察研究,招募40家医院因血尿转诊的患者。
- 所有患者接受膀胱镜和上尿路影像学检查(RBUS和/或CTU),其中567例(15.9%)行尿细胞学检查并纳入亚组分析。
- 膀胱癌和UTUC的诊断参考标准为组织学确诊癌症。
主要发现
- 567例患者中诊断膀胱癌39例(6.9%)、UTUC 8例(1.4%)。
- 尿细胞学诊断膀胱癌和UTUC的敏感性43.5%、特异性95.7%、PPV 47.6%、NPV 94.9%。
- 漏诊21例膀胱癌和5例UTUC,漏诊膀胱癌中4例(19%)≥pT2、2例(9.5%)为G3 pT1、10例(47.6%)为G3/2 pTa、5例(23.8%)为G1 pTa。
- 高危癌症的敏感性 marginally 提高至57.7%。
- 尿细胞学联合CTU的敏感性90.2%、特异性94.9%,联合RBUS的敏感性66.7%、特异性96.7%。
临床怎么用
- 血尿检查中不应常规进行尿细胞学检查。
- 对于考虑尿细胞学的特定病例,应评估假阳性结果可能导致的全麻下有创检查风险。
局限性
- 仅15.9%的招募患者行尿细胞学检查,亚组分析可能存在选择偏倚。
- 尿细胞学阳性定义包括可疑肿瘤细胞或非典型细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the diagnostic accuracy of urinary cytology to diagnose bladder cancer and upper tract urothelial cancer (UTUC) as well as the outcome of patients with a positive urine cytology and normal haematuria investigations in patients in a multicentre prospective observational study of patients investigated for haematuria. PATIENT AND METHODS: The DETECT I study (clinicaltrials.gov NCT02676180) recruited patients presenting with haematuria following referral to secondary case at 40 hospitals. All patients had a cystoscopy and upper tract imaging (renal bladder ultrasound [RBUS] and/ or CT urogram [CTU]). Patients, where urine cytology were performed, were sub-analysed. The reference standard for the diagnosis of bladder cancer and UTUC was histological confirmation of cancer. A positive urine cytology was defined as a urine cytology suspicious for neoplastic cells or atypical cells. RESULTS: Of the 3 556 patients recruited, urine cytology was performed in 567 (15.9%) patients from nine hospitals. Median time between positive urine cytology and endoscopic tumour resection was 27 (IQR: 21.3-33.8) days. Bladder cancer was diagnosed in 39 (6.9%) patients and UTUC in 8 (1.4%) patients. The accuracy of urinary cytology for the diagnosis of bladder cancer and UTUC was: sensitivity 43.5%, specificity 95.7%, positive predictive value (PPV) 47.6% and negative predictive value (NPV) 94.9%. A total of 21 bladder cancers and 5 UTUC were missed. Bladder cancers missed according to grade and stage were as follows: 4 (19%) were ≥ pT2, 2 (9.5%) were G3 pT1, 10 (47.6%) were G3/2 pTa and 5 (23.8%) were G1 pTa. High-risk cancer was confirmed in 8 (38%) patients. There was a marginal improvement in sensitivity (57.7%) for high-risk cancers. When urine cytology was combined with imaging, the diagnostic performance improved with CTU (sensitivity 90.2%, specificity 94.9%) superior to RBUS (sensitivity 66.7%, specificity 96.7%). False positive cytology results were confirmed in 22 patients, of which 12 (54.5%) had further invasive tests and 5 (22.7%) had a repeat cytology. No cancer was identified in these patients during follow-up. CONCLUSIONS: Urine cytology will miss a significant number of muscle-invasive bladder cancer and high-risk disease. Our results suggest that urine cytology should not be routinely performed as part of haematuria investigations. The role of urine cytology in select cases should be considered in the context of the impact of a false positive result leading to further potentially invasive tests conducted under general anaesthesia.
引用
- Tan WS, Sarpong R, Khetrapal P, et al. Does urinary cytology have a role in haematuria investigations? BJU Int. 2018. PMID: 30003675. doi:10.1111/bju.14459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。